FRNM

Freenome Inc

15.99

Sep 25 • 3:59 PM ET -0.02 (-0.12%)

15.99

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Diagnostics & Research USA Small NASD

Peers: XGN IMDX BDSX MYGN BNR PRPO QUCY MDXH ADVB XWEL

| Held by: ARKG SCHA ITOT ONEQ SCHB TMED TNXT TSEE

Scroll to Statements

Index	-
Market Cap	1.72B
Enterprise Value	1.72B
Income	-0.76M
Sales	0.00M
Book/sh	7.64
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Jun 12, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.09
P/C	3904.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.20
Current Ratio	0.20
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.07
EPS next Y	-
EPS next Q	0.15
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-123.69%
Sales Y/Y TTM	-
EPS Q/Q	-116.28%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	29.11%
Insider Trans	0.00%
Inst Own	33.04%
Inst Trans	7.10%
ROA	-0.86%
ROE	-0.92%
ROIC	-0.97%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.05%
SMA50	18.17%
SMA200	29.27%
Trades

Shs Outstand	107.45M
Shs Float	76.17M
Short Float	2.23%
Short Ratio	2.26
Short Interest	1.70M
52W High	17.50 -8.63%
52W Low	9.95 60.70%
Volatility	5.81% 6.20%
ATR (14)	0.90
RSI (14)	58.04
Beta	0.45
Rel Volume	0.56
Avg Volume	751.57K
Volume	418,854

Perf Week	-6.55%
Perf Month	13.48%
Perf Quarter	46.29%
Perf Half Y	47.92%
Perf YTD	22.72%
Perf Year	50.85%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	18.00
Prev Close	16.01
Price	15.99
Change %	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-26	Initiated	Guggenheim	Buy	$21
Aug-18-26	Initiated	TD Cowen	Buy	$17
Aug-17-26	Initiated	Jefferies	Buy	$17
Aug-17-26	Initiated	BTIG Research	Buy	$17
Aug-14-26	Initiated	Leerink Partners	Outperform	$18

Aug-12-26 09:00AM	FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen Lung Cancer Screening Test (GlobeNewswire)
Jul-27-26 08:00AM	FDA Approves Freenome's SimpleScreen CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. (GlobeNewswire)

Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.

CEO & DirectorMr. Aaron Elliott Ph.D.

Co-Founder & Chief Product OfficerMr. Riley Ennis

Chief Financial OfficerMr. Linh H. Le

MHSMr. Cheng-Ho Lin M.D.

Chief Legal OfficerMr. Thomas F. Fitzpatrick J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FRNM

Freenome Inc

Upgrade your Finviz experience